SOPHiA GENETICS announced that it has expanded its work with CHU de Nîmes, a regional and university hospital located in the South of France. The hospital system will use the SOPHiA DDM? Platform to progress its pharmacogenomics research.

Pharmacogenomics research is a field of research that looks at how an individual's unique genetic profile can affect response to medications, with the long-term goal to support clinicians in their choice of drugs and doses to best treat their patients. CHU de Nîmes is a member of the French-speaking group RNPGx, an international organization of some of the top researchers in the field of pharmacogenomics. RNPGx aims to further the adoption and implementation of pharmacogenetics testing.

Top researchers from RNPGx member institutions collaborated with SOPHiA GENETICS to develop a pharmacogenomics panel. The panel is a targeted, capture-based NGS panel that will expedite the process of testing and accelerate pharmacogenomics research. Additionally, the analytical capabilities of the SOPHiA DDM ?

Platform provide CHU de Nîmes with streamlined insights to facilitate fast and accurate variant discovery and reporting. CHU de Nîmes also uses SOPHiA GENETICS' technology for its research and treatment planning for autism and research of blood cancers. With the expanded relationship, CHU de Nîmes will continue to retain ownership of its research database, building upon the work already done through its use of SOPHiA GENETICS and helping increase the team's expertise in a variety of research areas.